As the disruption of Akt signaling has been linked to the tumorigenicity of many types of cancer [23,24,25], the first FDA-approved anticancer agent designed to target Akt (Capivasertib) was used as a control to compare the Akt binding affinity and thermodynamics of the two phytochemical agents (Table 1). This evidence concerns the gene AKT1 and cancer.